PL213658B1 - Kompozycje farmaceutyczne zawierajace terapeutycznie skuteczna ilosc polipeptydu; kompozycje farmaceutyczne zawierajace terapeutycznie skuteczna ilosc kwasu nukleinowego; zastosowanie wspomnianych polipeptydów, czasteczek kwasu nukleinowego, kwasu nukleinowego i wektora zawierajacego kwas nukleinowy; sposoby diagnozowania dystrofii siatkówki; izolowany polipeptyd; sposób jego wytwarzania; oczyszczone przeciwcialo lub jego fragment oraz zestaw do diagnozowania dystrofii siatkówki - Google Patents

Kompozycje farmaceutyczne zawierajace terapeutycznie skuteczna ilosc polipeptydu; kompozycje farmaceutyczne zawierajace terapeutycznie skuteczna ilosc kwasu nukleinowego; zastosowanie wspomnianych polipeptydów, czasteczek kwasu nukleinowego, kwasu nukleinowego i wektora zawierajacego kwas nukleinowy; sposoby diagnozowania dystrofii siatkówki; izolowany polipeptyd; sposób jego wytwarzania; oczyszczone przeciwcialo lub jego fragment oraz zestaw do diagnozowania dystrofii siatkówki

Info

Publication number
PL213658B1
PL213658B1 PL364681A PL36468102A PL213658B1 PL 213658 B1 PL213658 B1 PL 213658B1 PL 364681 A PL364681 A PL 364681A PL 36468102 A PL36468102 A PL 36468102A PL 213658 B1 PL213658 B1 PL 213658B1
Authority
PL
Poland
Prior art keywords
seq
polypeptide
leu
retinal
cells
Prior art date
Application number
PL364681A
Other languages
English (en)
Polish (pl)
Other versions
PL364681A1 (en
Inventor
Hicks David
Léveillard Thierry
Mohand-Said Saddek
Alain Sahel José
Original Assignee
Novartis Ag
Universite Louis Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Universite Louis Pasteur filed Critical Novartis Ag
Publication of PL364681A1 publication Critical patent/PL364681A1/xx
Publication of PL213658B1 publication Critical patent/PL213658B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL364681A 2001-04-06 2002-04-05 Kompozycje farmaceutyczne zawierajace terapeutycznie skuteczna ilosc polipeptydu; kompozycje farmaceutyczne zawierajace terapeutycznie skuteczna ilosc kwasu nukleinowego; zastosowanie wspomnianych polipeptydów, czasteczek kwasu nukleinowego, kwasu nukleinowego i wektora zawierajacego kwas nukleinowy; sposoby diagnozowania dystrofii siatkówki; izolowany polipeptyd; sposób jego wytwarzania; oczyszczone przeciwcialo lub jego fragment oraz zestaw do diagnozowania dystrofii siatkówki PL213658B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0104712A FR2823221B1 (fr) 2001-04-06 2001-04-06 Sequences associees a la degenerescence retinienne et applications
PCT/EP2002/003810 WO2002081513A2 (en) 2001-04-06 2002-04-05 Disease-associated protein

Publications (2)

Publication Number Publication Date
PL364681A1 PL364681A1 (en) 2004-12-13
PL213658B1 true PL213658B1 (pl) 2013-04-30

Family

ID=8862037

Family Applications (1)

Application Number Title Priority Date Filing Date
PL364681A PL213658B1 (pl) 2001-04-06 2002-04-05 Kompozycje farmaceutyczne zawierajace terapeutycznie skuteczna ilosc polipeptydu; kompozycje farmaceutyczne zawierajace terapeutycznie skuteczna ilosc kwasu nukleinowego; zastosowanie wspomnianych polipeptydów, czasteczek kwasu nukleinowego, kwasu nukleinowego i wektora zawierajacego kwas nukleinowy; sposoby diagnozowania dystrofii siatkówki; izolowany polipeptyd; sposób jego wytwarzania; oczyszczone przeciwcialo lub jego fragment oraz zestaw do diagnozowania dystrofii siatkówki

Country Status (22)

Country Link
US (6) US7795387B2 (enExample)
EP (1) EP1379657B1 (enExample)
JP (2) JP4370428B2 (enExample)
KR (1) KR100913258B1 (enExample)
CN (1) CN1529753B (enExample)
AU (1) AU2002312794B8 (enExample)
BR (1) BRPI0208870B8 (enExample)
CA (1) CA2443345C (enExample)
CZ (1) CZ305800B6 (enExample)
EC (1) ECSP024345A (enExample)
ES (1) ES2597835T3 (enExample)
FR (1) FR2823221B1 (enExample)
HU (1) HU226307B1 (enExample)
IL (3) IL158013A0 (enExample)
MX (1) MXPA03009114A (enExample)
NO (1) NO331277B1 (enExample)
NZ (1) NZ528376A (enExample)
PL (1) PL213658B1 (enExample)
RU (1) RU2384586C2 (enExample)
SK (1) SK288465B6 (enExample)
WO (1) WO2002081513A2 (enExample)
ZA (1) ZA200307403B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2823221B1 (fr) * 2001-04-06 2004-04-02 Univ Pasteur Sequences associees a la degenerescence retinienne et applications
JP4559429B2 (ja) 2003-05-21 2010-10-06 ジェンザイム・コーポレーション 空キャプシドを実質的に含まない組換えａａｖビリオン調製物を生成するための方法
FR2870241B1 (fr) * 2004-05-13 2015-02-27 Novartis Ag Facteur de viabilite des cones derive des batonnets ou rdcvf et applications
EP2027889A1 (en) * 2007-06-05 2009-02-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) New neuronal viability factor and use thereof
WO2009146183A1 (en) * 2008-04-15 2009-12-03 Genzyme Corporation Methods to produce rod-derived cone viability factor (rdcvf)
JP5748223B2 (ja) * 2008-09-10 2015-07-15 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ニューロン生存因子およびその使用
EP2383286A1 (en) 2010-04-30 2011-11-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of retinal degenerative diseases
CN110777124A (zh) * 2011-10-27 2020-02-11 威尔斯达眼科制剂公司 编码视杆细胞来源的视锥细胞活力因子的载体
WO2013124477A1 (en) 2012-02-24 2013-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of retinal degenerative diseases
US10004780B2 (en) 2012-10-17 2018-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of age-related macular degeneration (AMD)
PT3027646T (pt) 2013-07-31 2018-10-16 Novartis Ag Novos vetores e métodos de seleção de células hospedeiras eucarióticas
JP6684343B2 (ja) * 2015-05-21 2020-04-22 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ニューロン生存因子の相乗組み合わせ及びその使用
WO2017120294A1 (en) 2016-01-05 2017-07-13 The Trustees Of The University Of Pennsylvania Methods and compositions for treatment of ocular disorders and blinding diseases
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
KR20260085174A (ko) 2016-10-11 2026-06-08 파마 싱크, 엘엘씨 짧은 형태의 간상체 유래 원추체 생존능 인자와 친수성 펩타이드 사이의 융합 단백질
JP7495756B2 (ja) * 2019-12-09 2024-06-05 北京中因科技有限公司 医薬の製造におけるＣＹＰ４Ｖ２およびＲｄＣＶＦの使用
CN111733174B (zh) * 2020-08-07 2021-02-09 北京大学第三医院（北京大学第三临床医学院） 一种分离的核酸分子及其用途
EP4366757A1 (en) * 2021-07-07 2024-05-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Synergistic combination of rdcfv2 and rdcvf2l for the treatment of tauopathies
CN113774019B (zh) * 2021-08-11 2024-02-13 东南大学 一种脐带血间充质干细胞无血清培养基、培养方法及其应用
CN121285568A (zh) 2023-03-30 2026-01-06 制药五有限责任公司 编码视杆细胞源性视锥细胞活力因子和人IgK信号序列的载体
WO2026072752A1 (en) 2024-09-27 2026-04-02 Pharma Cinq, Llc Rod-derived cone viability factor fusion protein

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4771036A (en) * 1986-02-10 1988-09-13 Trustees Of Columbia University In The City Of New York Method and ophthalmic composition for the prevention and reversal of cataracts
GB9701710D0 (en) 1997-01-28 1997-03-19 Karobio Ab Mammalian protein
US6106825A (en) * 1997-05-07 2000-08-22 University Of Florida Entomopoxvirus-vertebrate gene delivery vector and method
FR2784030B1 (fr) * 1998-10-02 2002-12-20 Inst Nat Sante Rech Med Utilisation de bloqueurs des canaux calciques et/ou cgmp-dependants pour le traitement de pathologies de la retine
FR2784898A1 (fr) * 1998-10-26 2000-04-28 Univ Pasteur Utilisation du gdnf pour le traitement de la degenerescence retinienne
EP1033405A3 (en) * 1999-02-25 2001-08-01 Ceres Incorporated Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
CA2402563A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
FR2823221B1 (fr) * 2001-04-06 2004-04-02 Univ Pasteur Sequences associees a la degenerescence retinienne et applications
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
JP5748223B2 (ja) 2008-09-10 2015-07-15 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ニューロン生存因子およびその使用

Also Published As

Publication number Publication date
CN1529753B (zh) 2013-06-12
PL364681A1 (en) 2004-12-13
SK12232003A3 (sk) 2004-03-02
NO20034452L (no) 2003-12-04
BRPI0208870B8 (pt) 2021-05-25
SK288465B6 (sk) 2017-06-02
RU2384586C2 (ru) 2010-03-20
US8071745B2 (en) 2011-12-06
US7795387B2 (en) 2010-09-14
HUP0303730A2 (en) 2006-02-28
FR2823221A1 (fr) 2002-10-11
EP1379657B1 (en) 2016-08-17
KR20030094317A (ko) 2003-12-11
CZ20032706A3 (cs) 2003-12-17
CA2443345A1 (en) 2002-10-17
RU2003130638A (ru) 2005-04-20
ZA200307403B (en) 2004-04-21
NZ528376A (en) 2005-09-30
US8114849B2 (en) 2012-02-14
NO331277B1 (no) 2011-11-14
JP2005502319A (ja) 2005-01-27
JP4370428B2 (ja) 2009-11-25
IL158013A (en) 2010-12-30
JP4571695B2 (ja) 2010-10-27
IL199316A (en) 2011-01-31
CA2443345C (en) 2012-12-04
US20080004231A1 (en) 2008-01-03
US20040204350A1 (en) 2004-10-14
US20120108523A1 (en) 2012-05-03
IL158013A0 (en) 2004-03-28
MXPA03009114A (es) 2004-11-22
NO20034452D0 (no) 2003-10-03
WO2002081513A2 (en) 2002-10-17
BR0208870A (pt) 2004-04-27
ECSP024345A (es) 2004-06-28
ES2597835T3 (es) 2017-01-23
CZ305800B6 (cs) 2016-03-23
BRPI0208870B1 (pt) 2016-01-12
US20090062188A1 (en) 2009-03-05
CN1529753A (zh) 2004-09-15
US8394756B2 (en) 2013-03-12
AU2002312794B8 (en) 2006-01-12
FR2823221B1 (fr) 2004-04-02
US20120108657A1 (en) 2012-05-03
US8957043B2 (en) 2015-02-17
JP2009232843A (ja) 2009-10-15
EP1379657A2 (en) 2004-01-14
WO2002081513A3 (en) 2003-05-01
KR100913258B1 (ko) 2009-08-21
US20130287738A1 (en) 2013-10-31
AU2002312794B2 (en) 2005-12-01
HU226307B1 (en) 2008-08-28
US8518695B2 (en) 2013-08-27

Similar Documents

Publication Publication Date Title
US8957043B2 (en) Methods of treating retinitis pigmentosa using nucleic acids encoding RDCVF1 or RDCVF2
US9353162B2 (en) Disease-associated proteins
AU2002312794A1 (en) Disease-associated protein
US20030134797A1 (en) Treating eye disorders using intestinal trefoil proteins
US20080045699A1 (en) Interleukin-1 Related Gene and Protein
US6635616B2 (en) Laminin 15
EP1339423A2 (en) Intraflagellar transport
HK1061692B (en) Disease-associated protein